Related references
Note: Only part of the references are listed.Psychedelics and connectedness
R. L. Carhart-Harris et al.
PSYCHOPHARMACOLOGY (2018)
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
R. L. Carhart-Harris et al.
PSYCHOPHARMACOLOGY (2018)
Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study
Geoffrey E. Noller et al.
AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE (2018)
Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes
Thomas Kingsley Brown et al.
AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE (2018)
Repeated intranasal ketamine for treatment-resistant depression - the way to go? Results from a pilot randomised controlled trial
Veronica Galvez et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2018)
The Meaning-Enhancing Properties of Psychedelics and Their Mediator Role in Psychedelic Therapy, Spirituality, and Creativity
Ido Hartogsohn
FRONTIERS IN NEUROSCIENCE (2018)
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression
Leor Roseman et al.
FRONTIERS IN PHARMACOLOGY (2018)
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial
Michael C. Mithoefer et al.
LANCET PSYCHIATRY (2018)
Psychological Formulation as an Alternative to Psychiatric Diagnosis
Lucy Johnstone
JOURNAL OF HUMANISTIC PSYCHOLOGY (2018)
Side-effects associated with ketamine use in depression: a systematic review
Brooke Short et al.
LANCET PSYCHIATRY (2018)
Is online information on ecstasy tablet content safe?
Ruben Q. Vrolijk et al.
ADDICTION (2017)
Psychedelics as Medicines: An Emerging New Paradigm
D. E. Nichols et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: a randomized, crossover trial
E. Dakwar et al.
MOLECULAR PSYCHIATRY (2017)
Alterations of consciousness and mystical-type experiences after acute LSD in humans
Matthias E. Liechti et al.
PSYCHOPHARMACOLOGY (2017)
Mental disorders as networks of problems: a review of recent insights
Eiko I. Fried et al.
SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY (2017)
Long-term follow-up of psilocybin-facilitated smoking cessation
Matthew W. Johnson et al.
AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE (2017)
History of anaesthesia The ketamine story - past, present and future
Georges Mion
EUROPEAN JOURNAL OF ANAESTHESIOLOGY (2017)
Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010
Nicholas S. Downing et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Safety pharmacology of acute MDMA administration in healthy subjects
Patrick Vizeli et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2017)
Who is Molly'? MDMA adulterants by product name and the impact of harm-reduction services at raves
Sarah Saleemi et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2017)
Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow
Candace R. Lewis et al.
NEUROIMAGE (2017)
Potential Therapeutic Effects of Psilocybin
Matthew W. Johnson et al.
NEUROTHERAPEUTICS (2017)
Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression
Samuel T. Wilkinson et al.
PSYCHOTHERAPY AND PSYCHOSOMATICS (2017)
All clear for the decisive trial of ecstasy in PTSD patients
Kai Kupferschmidt
SCIENCE (2017)
Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin
Michael M. Schartner et al.
SCIENTIFIC REPORTS (2017)
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms
Robin L. Carhart-Harris et al.
SCIENTIFIC REPORTS (2017)
Patients' Accounts of Increased Connectedness and Acceptance After Psilocybin for Treatment-Resistant Depression
Rosalind Watts et al.
JOURNAL OF HUMANISTIC PSYCHOLOGY (2017)
Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions
Frederick S. Barrett et al.
FRONTIERS IN PSYCHOLOGY (2017)
Psychedelic Psychotherapy: Insights From 25 Years of Research
William A. Richards
JOURNAL OF HUMANISTIC PSYCHOLOGY (2017)
Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis
Alexander B. Belser et al.
JOURNAL OF HUMANISTIC PSYCHOLOGY (2017)
Potential Psychiatric Uses for MDMA
B. B. Yazar-Klosinski et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Crystal Structure of an LSD-Bound Human Serotonin Receptor
Daniel Wacker et al.
CELL (2017)
Effects of Low-Dose and Very Low-Dose Ketamine among Patients with Major Depression: a Systematic Review and Meta-Analysis
Ying Xu et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2016)
Neuroscience and the future for mental health?
N. Rose
EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES (2016)
Finding the Elusive Psychiatric Lesion With 21st-Century Neuroanatomy: A Note of Caution
Daniel R. Weinberger et al.
AMERICAN JOURNAL OF PSYCHIATRY (2016)
Nonmedical use of prescription drugs in the European Union
Scott P. Novak et al.
BMC PSYCHIATRY (2016)
Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI)
Matthew M. Nour et al.
FRONTIERS IN HUMAN NEUROSCIENCE (2016)
Ketamine administration reduces amygdalo-hippocampal reactivity to emotional stimulation
Milan Scheidegger et al.
HUMAN BRAIN MAPPING (2016)
Can Exposure-Based CBT Extend the Effects of Intravenous Ketamine in Obsessive-Compulsive Disorder? An Open-Label Trial
Carolyn I. Rodriguez et al.
JOURNAL OF CLINICAL PSYCHIATRY (2016)
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
Roland R. Griffiths et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
Stephen Ross et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology
Ido Hartogsohn
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: A preliminary meta-analysis and comparison to prolonged exposure therapy
Timothy Amoroso et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories
T. Kishimoto et al.
PSYCHOLOGICAL MEDICINE (2016)
Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years
Rafael G. dos Santos et al.
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY (2016)
Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA
Michael C. Mithoefer et al.
LANCET PSYCHIATRY (2016)
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
Robin L. Carhart-Harris et al.
LANCET PSYCHIATRY (2016)
Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers
Rainer Kraehenmann et al.
BIOLOGICAL PSYCHIATRY (2015)
Ketamine as a novel treatment for major depressive disorder and bipolar depression: a systematic review and quantitative meta-analysis
Ellen E. Lee et al.
GENERAL HOSPITAL PSYCHIATRY (2015)
The use of ketamine as an antidepressant: a systematic review and meta-analysis
Caoimhe M. Coyle et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2015)
被撤回的出版物: Efficacy of Ketamine in Bipolar Depression: Systematic Review and Meta-analysis (Retracted article. See vol. 24, pg. 307, 2018)
Ajay K. Parsaik et al.
JOURNAL OF PSYCHIATRIC PRACTICE (2015)
Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population
Peter S. Hendricks et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2015)
Intimate insight: MDMA changes how people talk about significant others
Matthew J. Baggott et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2015)
Psychedelics not linked to mental health problems or suicidal behavior: A population study
Pal-Orjan Johansen et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2015)
Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences?
Tomislav Majic et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2015)
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Michael P. Bogenschutz et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2015)
The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation
Xaver Koenig et al.
MOLECULES (2015)
Meta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression
Bruno Romeo et al.
PSYCHIATRY RESEARCH (2015)
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial
J. W. Murrough et al.
PSYCHOLOGICAL MEDICINE (2015)
LSD enhances the emotional response to music
M. Kaelen et al.
PSYCHOPHARMACOLOGY (2015)
Brain disorders? Precisely
Thomas R. Insel et al.
SCIENCE (2015)
Research Domain Criteria (RDoC) and the DSM-Two Methodological Approaches to Mental Health Diagnosis
Helena Chmura Kraemer
JAMA PSYCHIATRY (2015)
Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review
Nicolas D. Iadarola et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2015)
Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression
Le-Ben Wan et al.
JOURNAL OF CLINICAL PSYCHIATRY (2015)
The Variability of Ecstasy Tablets Composition in Brazil
Loraine R. Togni et al.
JOURNAL OF FORENSIC SCIENCES (2015)
LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects
Peter Gasser et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2015)
A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes
A. McGirr et al.
PSYCHOLOGICAL MEDICINE (2015)
Prescription drug abuse: from epidemiology to public policy
R. Kathryn McHugh et al.
JOURNAL OF SUBSTANCE ABUSE TREATMENT (2015)
Anti-addiction drug ibogaine inhibits hERG channels: a cardiac arrhythmia risk
Xaver Koenig et al.
ADDICTION BIOLOGY (2014)
The NIMH Research Domain Criteria (RDoC) Project: Precision Medicine for Psychiatry
Thomas R. Insel
AMERICAN JOURNAL OF PSYCHIATRY (2014)
The Effects of Subanesthetic Ketamine Infusions on Motivation to Quit and Cue-Induced Craving in Cocaine-Dependent Research Volunteers
Elias Dakwar et al.
BIOLOGICAL PSYCHIATRY (2014)
EFFECTS OF KETAMINE ON EXPLICIT AND IMPLICIT SUICIDAL COGNITION: A RANDOMIZED CONTROLLED TRIAL IN TREATMENT-RESISTANT DEPRESSION
Rebecca B. Price et al.
DEPRESSION AND ANXIETY (2014)
The iatrogenic epidemic of prescription drug abuse: County-level determinants of opioid availability and abuse
Eric R. Wright et al.
DRUG AND ALCOHOL DEPENDENCE (2014)
Psilocybin - Summary of knowledge and new perspectives
Filip Tyls et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2014)
The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs
Robin L. Carhart-Harris et al.
FRONTIERS IN HUMAN NEUROSCIENCE (2014)
Enhanced Repertoire of Brain Dynamical States During the Psychedelic Experience
Enzo Tagliazucchi et al.
HUMAN BRAIN MAPPING (2014)
The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories
R. L. Carhart-Harris et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2014)
Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012
Nicholas S. Downing et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Do the dissociative side effects of ketamine mediate its antidepressant effects?
David A. Luckenbaugh et al.
JOURNAL OF AFFECTIVE DISORDERS (2014)
Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases
Peter Gasser et al.
JOURNAL OF NERVOUS AND MENTAL DISEASE (2014)
Improvement in suicidal ideation after ketamine infusion: Relationship to reductions in depression and anxiety
Elizabeth D. Ballard et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2014)
Treating drug dependence with the aid of ibogaine: A retrospective study
Eduardo Ekman Schenberg et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2014)
Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision
Peter S. Hendricks et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2014)
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction
Matthew W. Johnson et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2014)
Ketamine administration in depressive disorders: a systematic review and meta-analysis
Guillaume Fond et al.
PSYCHOPHARMACOLOGY (2014)
RDoC is necessary, but very oversold
Allen Frances
WORLD PSYCHIATRY (2014)
Wittgenstein's nightmare: why the RDoC grid needs a conceptual dimension
Jerome C. Wakefield
WORLD PSYCHIATRY (2014)
The RDoC program: psychiatry without psyche?
Josef Parnas
WORLD PSYCHIATRY (2014)
Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder A Randomized Clinical Trial
Adriana Feder et al.
JAMA PSYCHIATRY (2014)
An alternative to current psychiatric classifications: a psychological landscape hypothesis based on an integrative, dynamical and multidimensional approach
Thomas Lefevre et al.
PHILOSOPHY ETHICS AND HUMANITIES IN MEDICINE (2014)
From Hofmann to the Haight Ashbury, and into the Future: The Past and Potential of Lysergic Acid Diethlyamide
David E. Smith et al.
JOURNAL OF PSYCHOACTIVE DRUGS (2014)
Medication nonadherence and psychiatry
Sarah C. E. Chapman et al.
CURRENT OPINION IN PSYCHIATRY (2013)
The increasing burden of mental and neurological disorders
Ferran Catala-Lopez et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2013)
Broadband Cortical Desynchronization Underlies the Human Psychedelic State
Suresh D. Muthukumaraswamy et al.
JOURNAL OF NEUROSCIENCE (2013)
Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study
Michael C. Mithoefer et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2013)
A randomized, controlled pilot study of MDMA (+/- 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD)
Peter Oehen et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2013)
Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010
Harvey A. Whiteford et al.
LANCET (2013)
Effects of Schedule I drug laws on neuroscience research and treatment innovation
David J. Nutt et al.
NATURE REVIEWS NEUROSCIENCE (2013)
DSM-5 and RDoC: progress in psychiatry research?
B. J. Casey et al.
NATURE REVIEWS NEUROSCIENCE (2013)
Randomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept
Carolyn I. Rodriguez et al.
NEUROPSYCHOPHARMACOLOGY (2013)
Psychedelics and Mental Health: A Population Study
Teri S. Krebs et al.
PLOS ONE (2013)
Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis
Goran Medic et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2013)
Beyond Brain Mapping: Using Neural Measures to Predict Real-World Outcomes
Elliot T. Berkman et al.
CURRENT DIRECTIONS IN PSYCHOLOGICAL SCIENCE (2013)
The biomedical model of mental disorder: A critical analysis of its validity, utility, and effects on psychotherapy research
Brett J. Deacon
CLINICAL PSYCHOLOGY REVIEW (2013)
Effects of Ketamine in Treatment-Refractory Obsessive-Compulsive Disorder
Michael H. Bloch et al.
BIOLOGICAL PSYCHIATRY (2012)
Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers
Matthew W. Johnson et al.
DRUG AND ALCOHOL DEPENDENCE (2012)
Fatalities Temporally Associated with the Ingestion of Ibogaine
Kenneth R. Alper et al.
JOURNAL OF FORENSIC SCIENCES (2012)
Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Teri S. Krebs et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2012)
The Challenges and Promise of Neuroimaging in Psychiatry
David E. J. Linden
NEURON (2012)
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Charles S. Grob et al.
ARCHIVES OF GENERAL PSYCHIATRY (2011)
Vanishing clinical psychopharmacology
Joop van Gerven et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Variability in the 3,4-methylenedioxymethamphetamine content of 'ecstasy' tablets in the UK
David Michael Wood et al.
EMERGENCY MEDICINE JOURNAL (2011)
The safety and efficacy of ± 3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study
Michael C. Mithoefer et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2011)
Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies
Erich Studerus et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2011)
Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness
Katherine A. MacLean et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2011)
Harm potential of magic mushroom use: A review
Jan van Amsterdam et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2011)
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Roland R. Griffiths et al.
PSYCHOPHARMACOLOGY (2011)
National Trends in Psychotropic Medication Polypharmacy in Office-Based Psychiatry
Ramin Mojtabai et al.
ARCHIVES OF GENERAL PSYCHIATRY (2010)
A UK strategy for mental health and wellbeing
Barbara J. Sahakian et al.
LANCET (2010)
Drug harms in the UK: a multicriteria decision analysis
David J. Nutt et al.
LANCET (2010)
OPINION The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Franz X. Vollenweider et al.
NATURE REVIEWS NEUROSCIENCE (2010)
Is Pharma Running Out of Brainy Ideas?
Greg Miller
SCIENCE (2010)
Content of ecstasy in the Netherlands: 1993-2008
Neeltje Vogels et al.
ADDICTION (2009)
LSD-assisted psychotherapy in persons suffering from anxiety associated with advanced-stage life threatening diseases. A phase-II, double-blind, placebo-controlled dose-response pilot study
Torsten Passie et al.
CNS NEUROSCIENCE & THERAPEUTICS (2008)
Human hallucinogen research: guidelines for safety
M. W. Johnson et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2008)
MDMA-Assisted Psychotherapy Using Low Doses in a Small Sample of Women with Chronic Posttraumatic Stress Disorder
Jose Carlos Bouso et al.
JOURNAL OF PSYCHOACTIVE DRUGS (2008)
Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence
Evgeny M. Krupitsky et al.
JOURNAL OF PSYCHOACTIVE DRUGS (2007)
Flashback: Psychiatric experimentation with LSD in historical perspective
E Dyck
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE (2005)
Comparison of acute lethal toxicity of commonly abused psychoactive substances
RS Gable
ADDICTION (2004)
Share Paper
